A5071158497- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Breast Lesions and Carcinomas
- Cancer Risks and Factors
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Genomics and Diagnostics
- Chemotherapy-related skin toxicity
- Neutropenia and Cancer Infections
- BRCA gene mutations in cancer
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Breast Implant and Reconstruction
- Monoclonal and Polyclonal Antibodies Research
- Global Cancer Incidence and Screening
- Brain Metastases and Treatment
- Male Breast Health Studies
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Colorectal Cancer Treatments and Studies
- Economic and Financial Impacts of Cancer
The University of Texas MD Anderson Cancer Center
2013-2023
Breast Cancer Care
2005-2017
Massachusetts General Hospital
1999-2017
Institute of Cancer Research
2009-2017
Mayo Clinic in Florida
2010-2017
Mayo Clinic in Arizona
2010-2017
Memorial Sloan Kettering Cancer Center
2001-2017
Rotkreuzklinikum München
2017
American Cancer Society
2017
RIKEN Center for Integrative Medical Sciences
2017
To measure residual disease after neoadjuvant chemotherapy in order to improve the prognostic information that can be obtained from evaluating pathologic response.Pathologic slides and reports were reviewed 382 patients two different treatment cohorts: sequential paclitaxel (T) then fluorouracil, doxorubicin, cyclophosphamide (FAC) 241 patients; a single regimen of FAC 141 patients. Residual cancer burden (RCB) was calculated as continuous index combining measurements primary tumor (size...
PURPOSE: To assess patient and tumor characteristics associated with a complete pathologic response (pCR) in both the breast axillary lymph node specimens outcome of patients found to have pCR after neoadjuvant chemotherapy for locally advanced cancer (LABC). PATIENTS AND METHODS: Three hundred seventy-two LABC received treatment two prospective trials using four cycles doxorubicin-containing chemotherapy. Patients had total mastectomy dissection or segmental followed by more additional then...
Purpose The objective of this study was to determine whether the addition trastuzumab chemotherapy in neoadjuvant setting could increase pathologic complete response (pCR) rate patients with human epidermal growth factor receptor 2 (HER2) –positive disease. Patients and Methods Forty-two HER2-positive disease operable breast cancer were randomly assigned either four cycles paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide or same simultaneous weekly for 24 weeks. primary...
PURPOSE: The efficacy and tolerability of anastrozole (Arimidex; AstraZeneca, Wilmington, DE, Macclesfield, United Kingdom) tamoxifen were compared as first-line therapy for advanced breast cancer in 353 postmenopausal women. PATIENTS AND METHODS: randomized, double-blind, multicenter study was designed to evaluate 1 mg once daily relative 20 patients with hormone receptor–positive tumors or unknown receptor status who eligible endocrine therapy. Primary end points objective response (OR),...
Abstract BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen terms disease‐free survival (DFS), time recurrence (TTR), and incidence contralateral cancer (CLBC). In current article, results efficacy update, based on a median follow‐up period 47 months, are reported along an...
Taxol, an antimicrotubule agent, has shown promise for efficacy in treatment of breast cancer, but severe hypersensitivity reactions led to cessation many phase I clinical trials. Consequently, investigators and the National Cancer Institute recommended that II studies this agent use 24-hour infusions antiallergic medications. Using a premedication regimen effective preventing reactions, we have performed trial taxol patients with metastatic cancer. Taxol was administered 25 at dose 250 mg/m...
PURPOSE: Capecitabine is a novel, oral, selectively tumor-activated fluoropyrimidine carbamate. This large multicenter phase II trial tested the efficacy and safety of twice-daily oral capecitabine at 2,510 mg/m 2 /d given for weeks followed by 1-week rest period repeated in 3-week cycles, patients with paclitaxel-refractory metastatic breast cancer. PATIENTS AND METHODS: Patients were to have received least two but not more than three prior chemotherapeutic regimens, one which had contained...
Abstract BACKGROUND Male breast carcinoma is an uncommon disease, and most previous studies have been single‐institution series that were limited by extremely small sample sizes. The goals of the current study to fill in major gaps knowledge regarding incidence, presenting characteristics, prognostic factors, survival rates male determine how differs between men women. METHODS Data from National Cancer Institute Surveillance, Epidemiology, End Results 1973–1998 database used. Age‐adjusted...
To determine the long-term clinical course of patients with metastatic breast cancer (MBC) who achieved a complete remission doxorubicin-alkylating agent-containing combination chemotherapy programs.To assess prognosis MBC, we reviewed our experience 1,581 treated on consecutive doxorubicin and alkylating front-line treatment protocols between 1973 1982. Treatment was administered for maximum duration 2 years. Characteristics survivors were evaluated, hazard rates progression calculated.From...
PURPOSE The purpose of this study was to determine whether trastuzumab improves prognosis women with metastatic human epidermal growth factor receptor 2 (HER2)/neu -positive breast cancer beyond that HER2/neu-negative disease. PATIENTS AND METHODS Two thousand ninety-one diagnosed from 1991 2007, known HER2/neu status and who had not received in the adjuvant setting, were identified. Disease classified into following three groups: negative, positive without first-line treatment, treatment....
Purpose To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in tamoxifen and anastrozole arms Arimidex, Tamoxifen, Alone or Combination (ATAC) Trial. Patients Methods RNA was extracted from 1,372 tumor blocks postmenopausal patients with hormone receptor–positive primary breast cancer monotherapy ATAC. Twenty-one genes were assessed by quantitative reverse transcriptase polymerase chain reaction, RS calculated. Cox proportional...
Purpose We recently reported that the mRNA-based, 21-gene Genomic Health recurrence score (GHI-RS) provided additional prognostic information regarding distant beyond obtained from classical clinicopathologic factors (age, nodal status, tumor size, grade, endocrine treatment) in women with early breast cancer, confirming earlier reports. The aim of this article is to determine how much contained standard immunohistochemical (IHC) markers. Patients and Methods primary cohort comprised 1,125...
We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy assessed its predictive accuracy on independent cases.One hundred thirty-three patients with stage I-III breast cancer were included. Pretreatment gene expression profiling was performed oligonecleotide microarrays fine-needle aspiration specimens. predictors pCR from 82 cases 51 cases.Overall rate 26% in both cohorts....
PURPOSE: To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in treatment advanced breast cancer patients whose disease progresses on prior endocrine treatment. PATIENTS AND METHODS: In this double-blind, double-dummy, parallel-group study, postmenopausal were randomized to receive either an intramuscular injection 250 mg once monthly or a daily oral dose 1 mg. The primary end point was time progression (TTP). Secondary points included objective...
Purpose To determine the long-term prognosis in each phenotypic subset of breast cancer related to residual burden (RCB) after neoadjuvant chemotherapy alone, or with concurrent human epidermal growth factor receptor 2 (HER2)-targeted treatment. Methods We conducted a pathologic review measure continuous RCB index (wherein complete response has = 0; disease is categorized into three predefined classes [RCB-I, RCB-II, and RCB-III]), yp-stage disease. Patients were prospectively observed for...
Purpose To evaluate whether hormonal receptor (HR) status can influence the prognostic significance of pathologic complete response (pCR). Patients and Methods This retrospective analysis included 1,731 patients with stage I to III noninflammatory breast cancer treated between 1988 2005 primary chemotherapy (PC). Ninety-one percent received anthracycline-based PC, 66% additional taxane therapy. pCR was defined as no evidence invasive tumor in axillary lymph nodes. Results Median age 49 years...
BACKGROUND Two randomized, double-blind trials have compared tamoxifen 20 mg daily and the selective, nonsteroidal aromatase inhibitor anastrozole 1 as first-line therapy for advanced breast carcinoma (ABC) in postmenopausal women. The were prospectively designed to allow combined data analyses. METHODS study population included 1021 women (median age, 67 years [range, 30–92]) with ABC whose tumors either estrogen and/or progesterone receptor positive or of unknown status. Primary endpoints...
Despite advances in therapies for breast cancer, improvement survival patients with recurrent or metastatic cancer has been difficult to establish. The objective of the current study was determine whether women improved from 1974 2000.The authors analyzed experience 834 who developed between November and December 2000. All had treated previously adjuvant anthracycline-based protocols. Patients were divided into five consecutive groups based on year recurrence, compared across groups. Because...
Thirty-eight patients with advanced breast cancer, multiple myeloma, and malignant lymphoma were treated partially purified (about 0.1%) leukocyte interferon. Patients a remission-induction schedule of 3 million to 9 antiviral units daily intramuscularly for 4 26 weeks. Responding maintained on U three times weekly. Tumor regression was observed in seven 17 cancer. Six 10 myeloma responded decrease at least 50% serum protein levels or Bence Jones excretion. the 11 achieved tumor regression....
Purpose The third-generation nonsteroidal aromatase inhibitors (AIs) are increasingly used as adjuvant and first-line advanced therapy for postmenopausal, hormone receptor–positive (HR+) breast cancer. Because many patients subsequently experience progression or relapse, it is important to identify agents with efficacy after AI failure. Materials Methods Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT) a randomized, double-blind, placebo controlled, multicenter phase III trial...